Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467770 | 1.00 | NPC1 (0.46) | NPC1CSNK2A1LMNAKDM4EMEN1 | |
| SCHEMBL25310440 | 0.93 | NPC1 (0.47) | NPC1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL24252789 | 0.85 | SYK (0.44) | NPC1CSNK2A1LMNAKDM4EMEN1 | |
| SCHEMBL24253013 | 0.79 | NPC1 (0.43) | NPC1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL30452027 | 0.79 | NPC1 (0.43) | NPC1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL30680289 | 0.79 | CSNK2A1 (0.47) | CSNK2A1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL23486482 | 0.79 | CSNK2A1 (0.47) | CSNK2A1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL14785370 | 0.78 | CSNK2A1 (0.44) | CSNK2A1SLC6A4HTR6 | |
| SCHEMBL24252902 | 0.78 | MEN1 (0.40) | NPC1LMNAKDM4EMEN1ALDH1A1 | |
| SCHEMBL30451591 | 0.78 | MEN1 (0.40) | NPC1LMNAKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | NPC1 460/4885CSNK2A1 3902/4885LMNA 3767/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | NPC1 460/4885CSNK2A1 3902/4885LMNA 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.